Keeping weight off after stopping weight-loss medication can be difficult, even for people who have made meaningful progress. Now, researchers are investigating an experimental injection that targets fat cells directly, raising questions about whether a different approach could help people manage abdominal fat over the longer term.
The treatment, known as CBL-514, has produced encouraging findings in early human trials. Researchers have reported reductions in fat beneath the skin and deeper abdominal fat linked to metabolic health. Animal studies have also suggested that the injection could help limit weight regain after certain medications are discontinued, although that possibility has not yet been established in humans.
How CBL-514 Takes A Different Approach To Fat Loss
Many weight-loss medications work by influencing appetite, digestion, or other processes involved in regulating body weight. CBL-514 takes a different approach by targeting adipocytes, the cells responsible for storing fat in the body. The experimental drug triggers apoptosis, a natural biological process that causes selected cells to break down and die.
The treatment is administered through injections into the lower abdominal area. During phase 2 clinical trials, participants received injections every three weeks for up to 12 weeks. The number of injections depended on the thickness of their abdominal fat, with fewer injections needed as the treated fat layer became thinner.
What Happens When Fat Cells Self-Destruct?
Fat cells store energy and can change in size as the body gains or loses weight. Many conventional weight-management strategies influence how much energy the body stores or uses, which can change the amount of fat held within these cells. CBL-514 is designed to reduce the number of fat cells in the treated area by triggering their natural destruction.
Researchers hope that this targeted mechanism could offer another option for reducing abdominal fat without surgery. However, the treatment remains experimental, and its effects on overall body weight, long-term metabolic health, and the body’s ability to store fat elsewhere require further investigation.
CBL-514 was initially developed to remove lipomas, which are fatty lumps that form beneath the skin. Researchers are now investigating whether its targeted action could have wider applications in fat reduction and obesity treatment.
Early Human Trials Show Reductions In Abdominal Fat
Two phase 2 clinical trials, identified as CBL-0204 and CBL-0205, examined CBL-514’s ability to reduce subcutaneous fat. This is the layer of fat directly beneath the skin that people can usually pinch around their abdomen. The findings suggested that the treatment could produce measurable reductions in this type of fat among participants who received the injections.
At the eight-week follow-up, 69.6% of participants treated with CBL-514 had achieved a reduction of at least 150 milliliters in subcutaneous fat volume. None of the participants receiving a placebo reached that threshold. These findings offered an encouraging early indication that the injection could reduce fat in the treated area.
Researchers also wanted to understand whether CBL-514 could affect visceral fat, which is stored deeper inside the abdomen. Unlike subcutaneous fat, visceral fat surrounds internal organs and is associated with several metabolic health concerns. Investigating changes in this deeper fat depot could help researchers understand whether the treatment has benefits beyond visible abdominal fat reduction.
The Numbers Behind The Visceral Fat Findings
For the visceral-fat analysis, researchers examined MRI data from a subgroup of 41 participants in the original trials. Twenty-three received CBL-514, while 18 were initially assigned to the placebo group. Data from 17 placebo recipients were available for the later comparison. Participants received injections into the lower abdomen every three weeks for up to 12 weeks, with doses reaching 600 milligrams.
The results showed different patterns of visceral fat volume between the treatment and placebo groups. Four weeks after the final injection, the CBL-514 group recorded an average reduction of 12.01% from baseline. Over the same period, the placebo group experienced an average increase of 5.68%, producing a between-group difference of 17.69 percentage points.
The difference remained evident at the later follow-up, although the timing varied between the two trials. Visceral fat volume was 10.45% below baseline in the CBL-514 group, while the placebo group recorded an average increase of 11.76%. The between-group difference was 22.21 percentage points.
These figures describe changes in visceral fat volume, not equivalent percentages of total body weight lost. The analysis also involved a relatively small subgroup, so larger studies will be needed to establish how consistently these results can be reproduced in broader populations.
Why Hidden Belly Fat Deserves Attention
Abdominal fat comes in different forms, and understanding the distinction helps explain why researchers are interested in this treatment. Subcutaneous fat sits immediately beneath the skin and contributes to the softer layer around the abdomen. Although it can influence body shape, its presence does not tell the full story about a person’s metabolic health.
Visceral fat is located deeper inside the abdominal cavity, surrounding organs such as the liver and intestines. It is metabolically active and is associated with insulin resistance, type 2 diabetes, and cardiovascular conditions. Excess visceral fat can therefore be an important consideration when assessing a person’s overall health risks.
Researchers are interested in whether CBL-514 can reduce this deeper fat because the potential benefits could extend beyond changes in appearance. However, a reduction in measured visceral fat does not automatically prove that a treatment will prevent diabetes, reduce heart attack risk, or improve long-term health outcomes. Those benefits must be demonstrated through additional research.
Fat Loss Is About More Than Appearance
A reduction in abdominal fat may affect how clothing fits or how a person feels about their appearance, but researchers are also interested in possible changes to metabolic health. Dr. W. Timothy Garvey, an endocrinologist at the University of Alabama at Birmingham who led the research, highlighted the distinction when discussing the findings.
“We expect that patients will be pleased by the cosmetic effects, such as the flatter stomach that can come with subcutaneous fat loss,” Garvey said. He also emphasized the potential importance of reducing body weight and visceral fat, alongside improvements in blood pressure and cholesterol.
These are potential health benefits rather than confirmed outcomes of the visceral-fat analysis. Researchers will need to determine whether the reductions observed in the trials translate into measurable improvements in blood sugar regulation, blood pressure, cholesterol levels, and other health indicators. Longer follow-up will also help establish whether any benefits persist after treatment ends.
Could CBL-514 Help People Maintain Weight Loss?
Another question surrounding CBL-514 concerns weight regain after stopping GLP-1 medications. Treatments such as semaglutide and tirzepatide have become important options for managing obesity and certain related health conditions. They can help people lose weight, but maintaining that progress after treatment is discontinued can be challenging.
Researchers are investigating whether reducing the number of fat cells could offer an additional strategy for supporting longer-term weight management. The theory is that removing some fat cells might limit the body’s capacity to store fat again, potentially changing how quickly weight returns after medication ends. At present, however, this remains a hypothesis rather than an established effect in humans.
What Animal Studies Have Revealed
In preclinical experiments, rats receiving tirzepatide alongside CBL-514 lost more weight on average than rats treated with tirzepatide alone. Researchers also observed that rats given the combination regained less weight after tirzepatide was discontinued. These findings prompted further interest in whether the two treatments could eventually have complementary roles in weight management.
One possible explanation is that reducing the number of fat cells could limit the amount of fat that can be stored in the treated tissue. Researchers believe this may help explain the reduced weight regain observed in the animal experiments. However, the body’s weight regulation involves multiple biological processes, and the effect of removing fat cells may be more complicated than the current hypothesis suggests.
Crucially, the reduced weight regain has so far been demonstrated in animal studies, not confirmed in human clinical trials. Researchers must establish whether a similar effect occurs in people, how long it might last, and whether the treatment produces any unintended metabolic consequences.
For people currently taking GLP-1 medications, these findings are not a reason to stop treatment or change a prescribed plan. Anyone considering a change to weight-management medication should discuss it with the healthcare professional overseeing their care.
What Researchers Know About Safety So Far
Early findings suggest that CBL-514 was generally well tolerated in the phase 2 research described by investigators. Most reported side effects involved temporary reactions around the injection site, including pain, swelling, and redness. These reactions were generally described as mild to moderate, and no serious adverse events were reported in the analyzed trials.
Although these initial safety findings are encouraging, they do not establish that the injection is safe for everyone or that its safety profile will remain the same with repeated use over longer periods. Larger studies are needed to identify less common adverse effects and assess whether the treatment creates risks that were not apparent in the smaller trials.
Important Questions Still Need Answers
Several issues remain unresolved as researchers continue studying the experimental injection. First, longer studies must establish how long reductions in abdominal fat persist after treatment ends. Researchers also need to determine whether the treatment can produce lasting improvements in metabolic health rather than simply changing measured fat volume.
Another important question concerns the possibility of fat accumulating in other organs or changes occurring in blood sugar and blood fat levels. These outcomes need careful assessment because a treatment that reduces fat in one location must still be evaluated for its effects on the body as a whole.
Researchers must also determine whether CBL-514 can help people maintain weight loss after stopping GLP-1 medication. That possibility remains particularly uncertain because the evidence currently comes from animal experiments. Human studies will need to assess the effectiveness of the treatment alongside its safety, durability, and potential role in longer-term weight management.
How CBL-514 Fits Into A Sustainable Weight-Loss Plan
For people working toward healthier weight management, CBL-514 represents an area of developing research rather than an available substitute for established care. Its early results are interesting, but the findings do not remove the need for practical habits that support health over time. Consistent routines can help people work toward their goals while the evidence for new treatments continues to develop.
A sustainable approach generally includes balanced meals, regular movement, adequate sleep, and realistic expectations about progress. The right combination varies depending on a person’s health, daily schedule, medical history, and individual needs. Extreme diets or unrealistic expectations can make it harder to maintain healthy habits over the long term.
People looking to build a practical routine can begin with manageable changes. Including vegetables, protein-rich foods, and fiber sources in balanced meals can support nutritional needs. Walking, cycling, swimming, or other enjoyable activities can make regular movement easier to maintain, while strength training can help preserve muscle and support physical function.
Sleep also deserves attention because consistent rest supports recovery, energy, and appetite regulation. People using prescription weight-loss medications may benefit from discussing their long-term goals and treatment options with their healthcare professional, particularly if they are concerned about regaining weight after treatment ends.
These habits do not guarantee a particular amount of weight loss, and individual results vary. They can nevertheless provide a useful foundation for maintaining health while researchers investigate whether treatments such as CBL-514 have a meaningful role in future obesity care.
Larger Clinical Trials Will Determine What Comes Next
CBL-514 has produced encouraging early findings, particularly in measurements of abdominal fat. The visceral-fat analysis showed a reduction among treated participants that remained evident at later follow-up, although the number of participants was small and the results require confirmation in larger studies.
Researchers have also reported promising animal findings involving the combination of CBL-514 and tirzepatide. The possibility that this approach could help reduce weight regain after medication stops is worth investigating, but there is not yet sufficient human evidence to establish that benefit.
Further clinical trials will need to determine whether the treatment can safely and consistently reduce abdominal fat in larger groups of people. They must also establish how durable the effects are and whether reductions in fat volume lead to meaningful improvements in health.
For now, the most useful takeaway is that scientists are exploring a different way to target abdominal fat, while important questions about long-term outcomes remain unanswered. CBL-514 may eventually become part of the conversation around weight management, but its place in treatment will depend on the results of rigorous human trials rather than early findings alone.
